⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439120 | 1.00 | — | — | |
| SCHEMBL349589 | 1.00 | — | — | |
| SCHEMBL341288 | 0.79 | — | — | |
| SCHEMBL27565101 | 0.74 | — | — | |
| SCHEMBL1888922 | 0.74 | — | — | |
| SCHEMBL1884735 | 0.74 | — | — | |
| SCHEMBL341064 | 0.74 | — | — | |
| Lesogaberan SCHEMBL349233 | 0.72 | — | — | |
| Lesogaberan SCHEMBL349234 | 0.72 | — | — | |
| Lesogaberan SCHEMBL348931 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | claimed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | claimed |
| US-20130251671-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-26 | — | — | US | claimed |
| EP-2621282-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | The Regents of the University of California (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012050907-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | WO | claimed |
| US-7807658-B2 | Use of GabaB receptor agonists | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | claimed |
| JP-3914435-B2 | — | — | 2007-05-16 | — | — | JP | claimed |
| US-20070021393-A1 | New use of GabaB receptor agonists | LEHMANN ANDERS | 2007-01-25 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-1240172-B1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2004-11-10 | — | — | EP | claimed |
| US-20030220303-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2003-11-27 | — | — | US | claimed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | claimed |
| JP-2003516407-A | — | — | 2003-05-13 | — | — | JP | claimed |
| WO-2002100869-A1 | NEW NAPSYLATE SALTS I | ASTRAZENECA AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | claimed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-11883436-B2 | Method of preparing hematopoietic stem and progenitor cells for transplantation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-01-30 | — | — | US | disclosed |
| US-11872200-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| CN-107050456-B | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | 加利福尼亚大学董事会 | 2022-08-12 | — | — | CN | disclosed |
| US-20220047639-A1 | Method of Preparing Hematopoietic Stem and Progenitor Cells for Transplantation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2022-02-17 | — | — | US | disclosed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | disclosed |
| US-10952980-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-2621282-B1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | UNIV CALIFORNIA (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200030272-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-01-30 | — | — | US | disclosed |
| US-10434078-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180250359-A1 | COMBINATION THERAPY USING GLIADIN AND GAMMA AMINOBUTYRIC ACID | DIAMYD MEDICAL AB (SE) | 2018-09-06 | — | — | US | disclosed |
| US-20180193295-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-12 | — | — | US | disclosed |
| US-9820955-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160081956-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-24 | — | — | US | disclosed |
| US-9089531-B2 | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130251671-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2621282-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | The Regents of the University of California (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012050907-A2 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | WO | disclosed |
| US-7807658-B2 | Use of GabaB receptor agonists | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-20080146836-A1 | New Aminopropylphosphinic acids | ELEBRING THOMAS | 2008-06-19 | — | — | US | disclosed |
| US-7319095-B2 | Use of GABAB receptor agonists | ASTRAZENECA AB (SE) | 2008-01-15 | — | — | US | disclosed |
| CN-101087614-A | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2007-12-12 | — | — | CN | disclosed |
| US-20070021393-A1 | New use of GabaB receptor agonists | LEHMANN ANDERS | 2007-01-25 | — | — | US | disclosed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | disclosed |
| US-20060172979-A1 | New use of GABAB receptor agonists | LEHMANN ANDERS | 2006-08-03 | — | — | US | disclosed |
| US-20060160777-A1 | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | US | disclosed |
| US-7034176-B2 | Aminopropylphosphinic acids | ASTRAZENECA AB (SE) | 2006-04-25 | — | — | US | disclosed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050137414-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2005-06-23 | — | — | US | disclosed |
| US-6841698-B2 | GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD | ASTRAZENECA AB (SE) | 2005-01-11 | — | — | US | disclosed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | disclosed |
| EP-1484333-A1 | New aminopropylphosphonous acids | AstraZeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1240172-B1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030220303-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | disclosed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |